Dysglycemia and the density of the coronary vasa vasorum

Diabetes Care

Volumn 42, Issue 5, 2019, Pages 980-982

  Gerstein, Hertzel C ^a   Nair, Vidhya ^a,b,c   Chaube, Ruchi ^a   Stoute, Heidi ^a   Werstuck, Geoff ^a  

^a HAMILTON HEALTH SCIENCES   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ARTERIAL WALL THICKNESS; ARTICLE; AUTOPSY; BLOOD VESSEL PARAMETERS; BLOOD VESSEL WALL; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DYSGLYCEMIA; FLUORESCENCE HISTOCHEMISTRY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEFT ANTERIOR DESCENDING CORONARY ARTERY; VASA VASORUM; AGED; ANIMAL; BLOOD; CELL COUNT; CORONARY ARTERY DISEASE; CORONARY BLOOD VESSEL; DISORDERS OF CARBOHYDRATE METABOLISM; FEMALE; GLUCOSE BLOOD LEVEL; HEART MUSCLE ISCHEMIA; INTIMA; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANIMALS; AUTOPSY; BLOOD GLUCOSE; CELL COUNT; CORONARY ARTERY DISEASE; CORONARY VESSELS; FEMALE; GLUCOSE METABOLISM DISORDERS; GLYCATED HEMOGLOBIN A; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; TUNICA INTIMA; VASA VASORUM;

EID: 85064934644     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc18-2483     Document Type: Article

References (12)

1. Gerstein HC, Werstuck GH. Dysglycaemia, vasculopenia, and the chronic consequences of diabetes. Lancet Diabetes Endocrinol 2013; 1:71–78
2. Veerman KJ, Venegas-Pino DE, Shi Y, Khan MI, Gerstein HC, Werstuck GH. Hyperglycaemia is associated with impaired vasa vasorum neovas-cularization and accelerated atherosclerosis in apolipoprotein-E deficient mice. Atherosclerosis 2013;227:250–258
3. Wang J, Chen H, Sun J, et al. Dynamic contrast-enhanced MR imaging of carotid vasa vasorum in relation to coronary and cerebrovascular events. Atherosclerosis 2017;263:420–426
4. Park KH, Sun T, Diez-Delhoyo F, et al. Association between coronary microvascular function and the vasa vasorum in patients with early coronary artery disease. Atherosclerosis 2016; 253:144–149
5. Ross S, Gerstein HC, Eikelboom J, Anand SS, Yusuf S, Paré G. Mendelian randomization analysis supports the causal role of dysglycaemia and diabetes in the risk of coronary artery disease. Eur Heart J 2015;36:1454–1462
6. Ahmad OS, Morris JA, Mujammami M, et al. A Mendelian randomization study of the effect of type-2 diabetes on coronary heart disease. Nat Commun 2015;6:7060
7. Benn M, Tybjaerg-Hansen A, McCarthy MI, Jensen GB, Grande P, Nordestgaard BG. Non-fasting glucose, ischemic heart disease, and myocardial infarction: a Mendelian randomization study. J Am Coll Cardiol 2012;59:2356–2365
8. Tancredi M, Rosengren A, Svensson AM, et al. Excess mortality among persons with type 2 diabetes. N Engl J Med 2015;373:1720–1732
9. Gerstein HC, Miller ME, Ismail-Beigi F, et al.; ACCORD Study Group. Effects of intensive gly-caemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial. Lancet 2014;384:1936–1941
10. Zoungas S, Arima H, Gerstein HC, et al.; Collaborators on Trials of Lowering Glucose (CONTROL) Group. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol 2017;5:431–437
11. Parma L, Baganha F, Quax PHA, de Vries MR. Plaque angiogenesis and intraplaque hemorrhage in atherosclerosis. Eur J Pharmacol 2017; 816:107–115
12. Buscombe JR. Exploring the nature of ath-eroma and cardiovascular inflammation in vivo using positron emission tomography (PET). Br J Radiol 2015;88:20140648